Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15196460 | 1.00 | HTR2A (0.47) | HTR2AHTR2CHTR2BTSHRPARP1 | |
| SCHEMBL29634686 | 1.00 | HTR2A (0.47) | HTR2AHTR2CHTR2BTSHRPARP1 | |
| SCHEMBL248563 | 1.00 | HTR2A (0.47) | HTR2AHTR2CHTR2BTSHRPARP1 | |
| SCHEMBL29478276 | 1.00 | HTR2A (0.47) | HTR2AHTR2CHTR2BTSHRPARP1 | |
| Toluene SCHEMBL28202213 | 0.86 | TSHR (0.47) | HTR2AHTR2CHTR2BTSHRPARP1 | |
| SCHEMBL25262338 | 0.81 | TSHR (0.40) | HTR2AHTR2CHTR2BTSHRPARP1 | |
| SCHEMBL29628352 | 0.81 | SLC6A2 (0.45) | TSHRPARP1GSTO1IDO1TDO2 | |
| SCHEMBL31068687 | 0.81 | ABCC9 (0.45) | TSHR | |
| SCHEMBL25303721 | 0.81 | ABCC9 (0.45) | TSHR | |
| SCHEMBL16462593 | 0.81 | GSTO1 (0.49) | TSHRPARP1GSTO1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111267451-B | Release film for high-capacity multilayer ceramic capacitor and method for producing same | 南亚塑胶工业股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-109956916-A | A kind of method preparing (S) -2- (3,4- difluorophenyl) ethylene oxide | 乐山职业技术学院 | 2019-07-02 | — | — | CN | claimed |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2026-02-12 | — | — | US | disclosed |
| EP-4463453-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2024-09-19 | — | — | US | disclosed |
| CN-111073919-B | Method for preparing (S) -2- (3, 4-difluorophenyl) oxirane | 尚科生物医药（上海）有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| WO-2008018823-A1 | A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007116101-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116099-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| EP-0611826-B1 | Processes for production of optically active epoxides | DAICEL CHEM (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-5672504-A | TREATING MIXED EPOXIDE ENANTIOMORPHS WITH MICROORGANISMS TO INCREASE CONCENTRATION OF OPTICALLY PURE S-ENANTIOMORPHS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-30 | — | — | US | disclosed |
| EP-0611826-A2 | Processes for production of optically active epoxides | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-24 | — | — | EP | disclosed |
| US-5225602-A | Catalytic rearrangement of phenyl-substituted epoxide | BASF AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | disclosed |
| US-4943667-A | DECYCLIZATION OF STYRENE OXIDE, HYDROGENATION CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1990-07-24 | — | — | US | disclosed |
| US-4929765-A | CATALYTIC REARRANGEMENT | BASF AKTIENGESELLSCHAFT (DE) | 1990-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | HTR2A 1968/4885HTR2C 1251/4885HTR2B 2102/4885 |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | BRAF, RAF1, NRAS | HTR2A 4109/4885HTR2C 2346/4885HTR2B 4597/4885 |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A2, SLC5A1 | HTR2A 183/4885HTR2C 202/4885HTR2B 191/4885 |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | HTR2A 1968/4885HTR2C 1251/4885HTR2B 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.